Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

25.99
+0.90003.59%
Volume:464.84K
Turnover:11.84M
Market Cap:2.93B
PE:-16.82
High:26.17
Open:24.82
Low:24.81
Close:25.09
52wk High:27.29
52wk Low:14.06
Shares:112.63M
Float Shares:64.72M
Volume Ratio:0.83
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5455
EPS(LYR):-2.5604
ROE:-28.43%
ROA:-17.12%
PB:3.76
PE(LYR):-10.15

Loading ...

Louise Kooij, Chief Accounting Officer, Reports Disposal of Common Shares of NewAmsterdam Pharma Company NV

Reuters
·
Sep 06

NewAmsterdam Pharma Company NV Publishes Document on Impact of Obicetrapib on Major Adverse Cardiovascular Events

Reuters
·
Sep 01

Core Scientific, NewAmsterdam Pharma, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Aug 30

NewAmsterdam Pharma Company NV Publishes Document on the Effect of Obicetrapib in Lipid-Lowering Therapy Trials

Reuters
·
Aug 29

Louise Kooij, Chief Accounting Officer, Reports Disposal of Common Shares in NewAmsterdam Pharma Company NV

Reuters
·
Aug 28

Chief Scientific Officer Johannes Jacob Pieter Kastelein Reports Disposal of Common Shares of NewAmsterdam Pharma Company NV

Reuters
·
Aug 26

NewAmsterdam Pharma to Present at European Society of Cardiology Congress 2025

Reuters
·
Aug 25

Wells Fargo Initiates Coverage on NewAmsterdam Pharma With Overweight Rating, $45 Price Target

MT Newswires Live
·
Aug 25

New Amsterdam Says EMA Accepts Application for Obicetrapib Therapy for Treating Hypercholesterolemia

MT Newswires Live
·
Aug 18

NewAmsterdam Pharma and Menarini's Obicetrapib Receives EMA Validation for Marketing Authorization Applications in Europe

Reuters
·
Aug 18

NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products

Reuters
·
Aug 16

Silence Therapeutics Announces Board Resignation and Appointment Changes

Reuters
·
Aug 14

Director James N. Topper Reports Acquisition of Common Shares of NewAmsterdam Pharma Company NV

Reuters
·
Aug 14

RBC Lifts Price Target on NewAmsterdam Pharma to $39 From $38, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Aug 07

NewAmsterdam Pharma Company NV reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 06

Earnings Flash (NAMS) NewAmsterdam Pharma Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.49 Loss

MT Newswires Live
·
Aug 06

NewAmsterdam Pharma Q2 EPS $(0.15) Beats $(0.46) Estimate, Sales $19.145M Beat $2.235M Estimate

Benzinga
·
Aug 06

NewAmsterdam Pharma Unveils Promising Results from BROADWAY Trial, Highlighting Obicetrapib’s Impact on Alzheimer’s Biomarkers

Reuters
·
Jul 30

Douglas F. Kling, Chief Operating Officer, Reports Disposal of Common Shares of NewAmsterdam Pharma Company NV

Reuters
·
Jul 18

Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target

MT Newswires Live
·
Jul 17